Pfizer sued Novo Nordisk, accusing it of using a $9 billion rival bid for Metsera to delay Pfizer’s $7.3 billion acquisition and stifle obesity-drug competition. Novo defended its offer as superior and compliant, while Metsera urged a judge to reject Pfizer’s attempt to block the deal.
